- US12077539utility2024Imidazole and Triazole KRAS Inhibitors0 cites
- US12071439utility2024Process and Intermediates for Preparing a JAK Inhibitor0 cites
- US12065494utility2024Combination Therapy Comprising an FGFR Inhibitor and a Nectin-4 Targeting Agent0 cites
- US12060433utility2024CD73 Inhibitor and A2A/A2B Adenosine Receptor Inhibitor Combination Therapy0 cites
- US12043614utility2024Salts of a Pim Kinase Inhibitor0 cites
- US12030884utility2024Pyrazoloquinoline KRAS Inhibitors0 cites
- US12030882utility2024Crystalline Solid Forms of a Bet Inhibitor0 cites
- US12030883utility2024Hetero-tricyclic Compounds as Inhibitors of KRAS0 cites
- US12030885utility2024Substituted Imidazo[2,1-f][1,2,4]triazines as Pi3k-gamma Inhibitors0 cites
- US12030889utility2024Imidazopyridazine and Imidazopyridine Compounds and Uses Thereof0 cites
- US12024517utility2024Salts of an FGFR Inhibitor0 cites
- US12018089utility2024Anti-cd73 Antibodies and Uses Thereof0 cites
- US12012409utility2024Bicyclic Heterocycles as FGFR Inhibitors0 cites
- US12005067utility2024JAK Inhibitor with a Vitamin D Analog for Treatment of Skin Diseases0 cites
- US12006320utility2024Heterocyclic Derivatives as PI3K Inhibitors0 cites
- US11999740utility2024Fused Pyrazine Derivatives as A2A / A2B Inhibitors0 cites
- US11999752utility2024Vinyl Imidazole Compounds as Inhibitors of KRAS0 cites
- US11992490utility2024Use of JAK1 Inhibitors for the Treatment of Cutaneous Lupus Erythematosus and Lichen Planus (LP)0 cites
- US11993654utility2024PD-1 Binding Domains0 cites
- US11981671utility2024Bicyclic Pyrazolyl Amines as CDK2 Inhibitors0 cites